復銳醫療科技(01696.HK)附屬及復星健康基金就投資天津星魅訂A輪投資協議
復銳醫療科技(01696.HK)公布,附屬復銳醫療天津作為原股東及A輪投資方,與復星健康基金(蘇州)及復星健康基金(天津)以及天津星魅生物科技(目標公司)訂立A輪投資協議,內容有關向目標公司累計出資1.09億元人民幣(下同),其中復銳醫療天津同意出資1,000萬元。
根據A輪投資協議,於A輪投資完成後,倘目標公司擬發行額外股份以籌集資金,且復星健康基金(蘇州)及復星健康基金(天津)擬參與此類融資,則復銳醫療天津亦將認購目標公司的額外股份,並按於A輪投資完成後其於目標公司的持股比例額外出資,惟復銳醫療天津的最高出資額不超過1,036.7萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.